Insider Trading activities of Puma Biotechnology, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Puma Biotechnology, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Puma Biotechnology, Inc. since year 2005. Table 2 shows the detailed insider transactions of Puma Biotechnology, Inc. since 2005. The reporting company's ticker symbol is PBYI. The reporting company's CIK number is 1401667.
The total value of stock buying since 2005 is $48,842,169.
The total value of stock sales since 2005 is $164,272,200.
The total value of stock option exercises since 2005 is $429,400.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Puma Biotechnology, Inc. (PBYI).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-12 0 $0 1,322 $139,424 0 $0
2017-09 0 $0 30,000 $3,301,400 30,000 $339,000
2017-07 0 $0 22,825 $2,128,089 5,000 $56,500
2017-06 0 $0 754,388 $64,712,034 0 $0
2017-05 0 $0 1,235,700 $92,970,603 0 $0
2017-02 0 $0 3,008 $95,729 0 $0
2017-01 0 $0 17,898 $594,837 0 $0
2015-07 0 $0 3,000 $330,084 3,000 $33,900
2014-04 30 $2,483 0 $0 0 $0
2013-11 303,249 $11,993,327 0 $0 0 $0
2013-10 140,900 $5,673,620 0 $0 0 $0
2012-12 200,000 $3,797,092 0 $0 0 $0
2012-10 620,000 $9,920,000 0 $0 0 $0
2012-07 786,424 $9,515,767 0 $0 0 $0
2012-06 169,000 $1,893,470 0 $0 0 $0
2012-05 13,500 $178,875 0 $0 0 $0
2012-04 422,195 $5,867,535 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Puma Biotechnology, Inc. insiders (PBYI)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-12-01 Eyler Charles R (SEE REMARKS) Sale 1,322 105.47 139,424
2017-09-29 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Sale 15,000 120.00 1,800,000
2017-09-29 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Option Ex 15,000 11.30 169,500
2017-09-07 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Sale 14,000 100.10 1,401,400
2017-09-07 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Option Ex 14,000 11.30 158,200
2017-09-06 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Sale 1,000 100.00 100,000
2017-09-06 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Option Ex 1,000 11.30 11,300
2017-07-20 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Sale 1,998 94.84 189,490
2017-07-20 Lo Steven (Chief Commercial Officer) Sale 1,990 94.90 188,852
2017-07-20 Auerbach Alan H (PRESIDENT AND CEO) Sale 13,175 94.97 1,251,256
2017-07-20 Eyler Charles R (SEE REMARKS) Sale 662 95.15 62,991
2017-07-03 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Sale 5,000 87.10 435,500
2017-07-03 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Option Ex 5,000 11.30 56,500
2017-06-12 Gross Phillip Sale 88,944 79.64 7,083,144
2017-06-09 Gross Phillip Sale 58,316 80.85 4,714,848
2017-06-08 Gross Phillip Sale 100,000 81.19 8,118,800
2017-06-05 Gross Phillip Sale 307,128 91.81 28,197,114
2017-06-02 Gross Phillip Sale 30,475 83.06 2,531,283
2017-06-01 Gross Phillip Sale 169,525 82.98 14,066,845
2017-05-26 Gross Phillip Sale 300,000 77.58 23,273,400
2017-05-25 Gross Phillip Sale 400,000 78.12 31,246,800
2017-05-24 Gross Phillip Sale 535,700 71.78 38,450,403
2017-02-01 Charnas Robert (Other) Sale 3,008 31.82 95,729
2017-01-20 Charnas Robert (Other) Sale 2,293 33.23 76,207
2017-01-20 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Sale 2,293 33.23 76,207
2017-01-20 Lo Steven (Chief Commercial Officer) Sale 2,290 33.23 76,108
2017-01-20 Auerbach Alan H (PRESIDENT AND CEO) Sale 10,202 33.23 339,063
2017-01-20 Eyler Charles R (SEE REMARKS) Sale 820 33.23 27,252
2015-07-06 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Sale 3,000 110.03 330,084
2015-07-06 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Option Ex 3,000 11.30 33,900
2014-04-11 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Buy 28 82.49 2,309
2014-04-09 Bryce Richard Paul (SR VP, CLINICAL RESEARCH & DEV) Buy 2 87.35 174
2013-11-08 Gross Phillip Buy 22,549 38.92 877,607
2013-11-05 Gross Phillip Buy 280,700 39.60 11,115,720
2013-10-09 Gross Phillip Buy 140,900 40.27 5,673,620
2012-12-18 Gross Phillip Buy 29,560 18.98 561,048
2012-12-12 Gross Phillip Buy 30,400 19.00 577,539
2012-12-11 Gross Phillip Buy 17,000 19.00 323,000
2012-12-10 Gross Phillip Buy 25,000 19.00 475,000
2012-12-07 Gross Phillip Buy 98,040 18.98 1,860,505
2012-10-24 Malley Thomas (Director) Buy 10,000 16.00 160,000
2012-10-18 Gross Phillip Buy 610,000 16.00 9,760,000
2012-07-27 Gross Phillip Buy 450,000 12.50 5,625,000
2012-07-25 Gross Phillip Buy 154,000 12.00 1,848,000
2012-07-16 Gross Phillip Buy 153,000 11.21 1,715,130
2012-07-03 Gross Phillip Buy 2,424 11.08 26,857
2012-07-02 Gross Phillip Buy 27,000 11.14 300,780
2012-06-29 Gross Phillip Buy 149,000 11.03 1,643,470
2012-06-11 Malley Thomas (Director) Buy 10,032 12.50 125,400
2012-06-08 Malley Thomas (Director) Buy 8,168 12.50 102,100
2012-06-07 Malley Thomas (Director) Buy 1,800 12.50 22,500
2012-05-03 Gross Phillip Buy 8,500 13.25 112,625
2012-05-01 Gross Phillip Buy 5,000 13.25 66,250
2012-04-30 Gross Phillip Buy 22,195 13.00 288,535
2012-04-26 Gross Phillip Buy 100,000 13.85 1,385,000
2012-04-25 Gross Phillip Buy 200,000 13.97 2,794,000
2012-04-24 Gross Phillip Buy 100,000 14.00 1,400,000

Insider trading activities including stock purchases, stock sales, and option exercises of PBYI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Puma Biotechnology, Inc. (symbol PBYI, CIK number 1401667) see the Securities and Exchange Commission (SEC) website.